322 related articles for article (PubMed ID: 25361077)
1. Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.
Corazzari M; Rapino F; Ciccosanti F; Giglio P; Antonioli M; Conti B; Fimia GM; Lovat PE; Piacentini M
Cell Death Differ; 2015 Jun; 22(6):946-58. PubMed ID: 25361077
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: Crosstalk and therapeutic targets in cutaneous melanoma.
Rather RA; Bhagat M; Singh SK
Mutat Res Rev Mutat Res; 2020; 785():108321. PubMed ID: 32800272
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
[TBL] [Abstract][Full Text] [Related]
5. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
Jang GH; Lee M
Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Ryabaya O; Prokofieva A; Khochenkov D; Abramov I; Zasedatelev A; Stepanova E
Oncol Rep; 2018 Jul; 40(1):385-394. PubMed ID: 29749510
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
Ahn JH; Lee YW; Ahn SK; Lee M
Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
[TBL] [Abstract][Full Text] [Related]
8. Dynamic interplay between autophagic flux and Akt during melanoma progression in vitro.
Maes H; Martin S; Verfaillie T; Agostinis P
Exp Dermatol; 2014 Feb; 23(2):101-6. PubMed ID: 24313465
[TBL] [Abstract][Full Text] [Related]
9. New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.
Ferretta A; Maida I; Guida S; Azzariti A; Porcelli L; Tommasi S; Zanna P; Cocco T; Guida M; Guida G
Biochim Biophys Acta; 2016 Nov; 1863(11):2710-2718. PubMed ID: 27542908
[TBL] [Abstract][Full Text] [Related]
10. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
11. The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma.
Liu X; Wu J; Qin H; Xu J
Target Oncol; 2018 Aug; 13(4):437-446. PubMed ID: 29667105
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance.
Li S; Song Y; Quach C; Guo H; Jang GB; Maazi H; Zhao S; Sands NA; Liu Q; In GK; Peng D; Yuan W; Machida K; Yu M; Akbari O; Hagiya A; Yang Y; Punj V; Tang L; Liang C
Nat Commun; 2019 Apr; 10(1):1693. PubMed ID: 30979895
[TBL] [Abstract][Full Text] [Related]
14. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
16. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
17. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
19. ER stress-induced autophagy in melanoma.
Meng XX; Yao M; Zhang XD; Xu HX; Dong Q
Clin Exp Pharmacol Physiol; 2015 Aug; 42(8):811-6. PubMed ID: 26096022
[TBL] [Abstract][Full Text] [Related]
20. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.
Fedorenko IV; Paraiso KH; Smalley KS
Biochem Pharmacol; 2011 Aug; 82(3):201-9. PubMed ID: 21635872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]